Amgen reports earnings today, and some traders have already chalked up profits in the stock.
Joe Jimenez, CEO of Novartis, tells CNBC that 2012 was a transition year for Novartis with 17 major drug approvals.
Johnson & Johnson reported earnings Tuesday that topped analysts' expectations, though revenue was in line with estimates.
After doing some research, the "Mad Money" host comments on stocks viewers wanted to know about.
The big U.S. and European drug companies are dealing with their own 'cliff' as blockbuster drugs lose their patent protection. But they are turning back to research and development to fill the gap.
Making the health care system function better could save $2 trillion on health costs over the next decade, Dr. David Blumenthal, Commonwealth Fund president, told CNBC on Friday.
Eli Lilly will be "very challenged" by the loss of exclusivity on several blockbuster drugs, CEO John Lechleiter told CNBC on Tuesday, but added the company can manage its growth in response.
Rock bottom interest rates will likely boost key stocks in the biotechnology sector, but Obamacare will dampen prospects for HMO shares.
"As a group, biotech is the place to be this year," said," Les Funtleyder, Poliwogg fund manager, discussing where to find attractive health care opportunities in 2013.
What a beautiful sight to behold - the stock chart, that is.
John Lechleiter, Chairman, President & CEO of Eli Lilly, discusses why he expects profits to rise this year despite a wave of patent expirations.
CNBC Contributor Barbara Ryan is taking the pulse of health care stocks at this year's "Woodstock" of health care.
Richard Pops, chairman & CEO at Alkermes, talks with CNBC's David Faber about positive developments in two key treatments in the company's pipeline.
Barbara Ryan, founder, Barbara Ryan Advisors, tells CNBC where investors should focus in the health care sector, from the JPMorgan Health Care Conference in San Francisco.
Eli Lilly said on Friday it expects 2013 earnings to increase to $3.75 to $3.90 per share excluding items.
As Christmas overeating gives way to under-fulfilled new year diets, the pharmaceutical industry's appetite has been whetted for a fresh surge in business.
It's hard to see how lawmakers can avoid touching health insurance if they want to eliminate loopholes and curtail deductions so as to raise revenue and lower tax rates.
Wondering how the market will first react, if and when we go over the fiscal cliff? Cramer thinks we may have just gotten an early glimpse.
Drug maker Baxter International said it will buy privately held Swedish company Gambro for about $2.76 billion to broaden its dialysis product portfolio.
Johnson & Johnson announced on Friday that it had elected a new chairman, with its current chair planning to step down within a month and retire shortly thereafter.